Neointimal hyperplasia inhibition effect of angiotensin II type 1 receptor blockers in patients after coronary stent implantation: A meta-analysis

American Journal of Cardiovascular Drugs

Volumn 11, Issue 3, 2011, Pages 209-213

  Kun, Xie ^a   Yong, Li ^a   Bo, Jin ^a   Hai Ming, Shi ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Angiotensin type 1 receptor antagonists; Coronary artery disease; Coronary stenting; Meta analysis; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; NITRATE; TICLOPIDINE; VALSARTAN;

ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; EMBASE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FOLLOW-UP STUDIES; HUMANS; HYPERPLASIA; NEOINTIMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; STENTS;

EID: 79957928330     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11591780-000000000-00000     Document Type: Article

References (30)

1. Yamada T, Kondo T, Numaguchi Y, et al.Angiotensin II receptor blocker inhibits neointimal hyperplasia through regulation of smooth muscle-like progenitor cells. Arterioscler Thromb Vasc Biol 2007; 27: 2363-9 (Pubitemid 350203951)
2. Ohtani K, Egashira K, Ihara Y, et al.Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells. Hypertension 2006; 48: 664-70 (Pubitemid 44843870)
3. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995; 25: 155-61
4. Wilensky RL. Angiotensin-receptor blockers: revival of the systemic prevention of restenosis? Cardiovasc Drug Ther 2003; 17: 63-73 (Pubitemid 36898099)
5. Iwata A, Miura SI, Imaizumi S, et al.Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J 2007; 71: 32-8 (Pubitemid 46045547)
6. Peters S. Comparison of efficacy of low- (80 mg/day) and high- (160- 320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Am J Cardiovasc Drugs 2008; 8: 83-7 (Pubitemid 351570858)
7. Hong SJ, Shim WJ, Choi J, et al.Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 2007; 100: 1625-9 (Pubitemid 350122328)
8. Sugihara M, Miura S, Takamiya Y, et al.Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009; 32: 625-30
9. Waseda K, Ozaki Y, Takashima H, et al.Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: an intravascular ultrasound study. Circ J 2006; 70: 1111-5 (Pubitemid 44386988)
10. Fujita M, Yarnazaki T,Hayashi D, et al.Comparison of cardiovascular events in patients with angiographically documented coronary narrowing with combined renin-angiotensin system inhibitor plus statin versus renin-angiotensin system inhibitor alone versus statin alone (from the Japanese Coronary Artery Disease Study)Am J Cardiol 2007; 100: 1750-3 (Pubitemid 350234791)
11. Jorgensen E, Kelbaek H, Helqvist S, et al.Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001; 38: 1434-9 (Pubitemid 33033023)
12. Yoshida O, Hirayama H, Nanasato M, et al.The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J 2005; 149: e2
13. NagasawaH, Mutoh M, Nogimura T, et al.Aprospective randomized study of the use of an oral angiotensin II receptor blocker to prevent restenosis after percutaneous coronary intervention. Jikeikai Med J 2005; 52: 15-20
14. Yoshikawa M, Nakamura K, Nagase S, et al.Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis. J Cardiovasc Pharmacol 2009; 53: 179-86
15. Nishikawa H, Miura S, Shimomura H, et al.Combined treatment with statin and angiotensin-receptor blocker after stenting as a useful strategy for prevention of coronary restenosis. J Cardiol 2005; 45: 107-13 (Pubitemid 40756206)
16. Peters S, TrummelM,Meyners W, et al.Valsartan versus ACE inhibition after bare metal stent implantation: results of the VALVACE trial. Int J Cardiol 2005; 98: 331-5 (Pubitemid 40431183)
17. Yokoyama J, Higuma T, Tomita H, et al.Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. Int J Cardiol 2009; 132: 114-20
18. Kramer J, Ruf RG, Schmidt S, et al.The CAIRP (CAndesartan for In-stent Restenosis Prevention) trial: a multicenter study of AT1-receptor blocker therapy in coronary stenting. J Invasive Cardiol 2008; 20: 205-10 (Pubitemid 351643265)
19. Radke PW, Figulla HR, Drexler H, et al.A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. Am Heart J 2006; 152: 761. e1-6
20. Ujiie Y, Hirosaka A, Mitsugi M, et al.Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis. Int Heart J 2006; 47: 173-84
21. Wakeyama T, Ogawa H, Iida H, et al.Effects of candesartan and probucol on restenosis after coronary stenting: results of Insight of Stent Intimal Hyperplasia Inhibition by New Angiotensin II Receptor Antagonist (ISHIN) trial. Circ J 2003; 67: 519-24 (Pubitemid 36705507)
22. Peters S, Gotting B, Trummel M, et al.Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13: 93-7 (Pubitemid 33761992)
23. Clozel JP, Hess P, Michael C, et al.Inhibition of converting enzyme and neointimal formation after vascular injury in rabbits and guinea pigs. Hypertension 1991; 18 (4 Suppl.): II55-9
24. Candipan RC, Hsiun PT, Pratt R, et al.Vascular injury augments adrenergic neurotransmission. Circulation 1994; 89: 777-84 (Pubitemid 24056206)
25. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992; 86: 100-1
26. Ribichini F, Wins W, Ferrero V, et al.Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting. Am J Cardiol 2003; 91: 154-8 (Pubitemid 36084299)
27. H. Vernon A, Janice M, Fred JC, et al.Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemicatherosclerotic canine coronary arteries. Circulation 2001; 104: 2331-7
28. Bysani C, Srinivas M, LeninM, et al.Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-k B- and AP-1- mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006; 281: 15099-109
29. Takayuki Y, Katsumi M, Takeshi K, et al.Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis 2004; 174: 253-9
30. Birgit J, Cornelia M, Stefan M, et al.Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 2005; 68: 483-92